Skip to main content
Premium Trial:

Request an Annual Quote

With Top Executives in Place, EraGen Sets Sights on Commercializing Tools

NEW YORK, Aug. 23 - With its functional-proteomics tools and nucleic-acid diagnostics ready to roll, EraGen Biosciences has completed building up its executive-management team.


Yesterday the company said Samraat Raha, former vice president of discovery services at Incyte Genomics, would be its first chief business officer, and earlier this month it hired Gary Madsen, a former manager at Abbott Labs, to be chief technical officer.

EraGen had named its first president and CEO, former GlaxoSmithKline executive Irene Hrusovsky, in February.


The firm said it is close to naming a new vice president of finance and a vice president of technical development and manufacturing.


EraGen's technology includes the Master Catalog proteomics data-mining and -analysis tool, the MultiCode and GeneCode genotyping tools, and the EraCode molecular recognition technology.


"Our next step is really to try and coordinate all the new people, try to work on the new goals that we have set," said Carly Owen, Hrusovsky's assistant.


It was not immediately clear when the company would begin rolling out its technology.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.